| Nov 14 |
Pharvaris reports Q3 results
|
| Nov 13 |
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
|
| Nov 12 |
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
|
| Oct 24 |
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
|
| Oct 16 |
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
|
| Oct 15 |
Pharvaris to Host Virtual Investor Event on October 23, 2024
|
| Oct 3 |
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
|
| Sep 5 |
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
|
| Sep 5 |
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
|
| Sep 5 |
Pharvaris Presents Data at the Bradykinin Symposium 2024
|
